title: A live bivalent influenza vaccine based on a H9N2 virus strain.
abstract: The purpose of this study was to construct an H9N2 virus-based bivalent live vaccine expressing the protective antigen of a different subtype of influenza virus. Reverse genetics was used to generate an influenza virus containing nine gene segments derived from the A/Chicken/Jiangsu/11/2002 (H9N2) strain, including independent M1 and M2 matrix gene segments. A recombinant virus expressing the H1N1 HA1 hemagglutinin protein was produced on this framework by substituting the extracellular domain of the H9N2 M2 gene with the H1N1 HA1 fragment from A/PR/8/34 (PR8, H1N1). The resulting hybrid virus H9N2-PR8/HA1 was genetically stable and of low pathogenicity. Intra-nasal immunization of BALB/c mice with H9N2-PR8/HA1 virus induced both anti-H9N2 virus and anti-PR8 HA antibodies and conferred protection to mice against lethal challenge (40x LD(50)) with either H1N1 or H9N2 viruses. This study provides a new influenza H9N2 virus model for the expression and/or delivery of foreign antigens.
authors.affiliation: State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, Hubei, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Wu
authors.forename: Yi
authors.initials: Y
authors.lastname: Guan
authors.forename: Zhongdong
authors.initials: Z
authors.lastname: Yang
authors.forename: Jianjun
authors.initials: J
authors.lastname: Chen
authors.forename: Hanzhong
authors.initials: H
authors.lastname: Wang
authors.forename: Quanjiao
authors.initials: Q
authors.lastname: Chen
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Sui
authors.forename: Fang
authors.initials: F
authors.lastname: Fang
authors.forename: Ze
authors.initials: Z
authors.lastname: Chen
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D016679:Genome, Viral; D053118:Influenza A Virus, H1N1 Subtype / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D053127:Influenza A Virus, H9N2 Subtype / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000517:prevention & control; D016019:Survival Analysis; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014764:Viral Proteins / Q000235:genetics; D014774:Virulence
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014764:Viral Proteins